Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donidalorsen in hereditary angioedema prophylaxis
NCT05392114Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 14
01
Overview
A Phase 3 trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Started Jul 2022; status: active, not recruiting.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05392114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392114.